Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase(®), the WHO Pharmacovigilance Database

SIMPLE SUMMARY: The development of oral cancer agents known as “tyrosine kinase inhibitors”—imatinib, dasatinib, nilotinib, bosutinib, and ponatinib—has considerably improved patient survival and quality of life in hematological cancers such as chronic myeloid leukemia. These drugs target a fusion p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cellier, Morgane, Bourneau-Martin, Delphine, Abbara, Chadi, Crosnier, Alexandre, Lagarce, Laurence, Garnier, Anne-Sophie, Briet, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093506/
https://www.ncbi.nlm.nih.gov/pubmed/37046701
http://dx.doi.org/10.3390/cancers15072041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093506/
https://www.ncbi.nlm.nih.gov/pubmed/37046701
http://dx.doi.org/10.3390/cancers15072041

Ejemplares similares